These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 18000219)

  • 21. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
    Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
    Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells.
    Chen X; Danes C; Lowe M; Herliczek TW; Keyomarsi K
    J Natl Cancer Inst; 2000 Sep; 92(17):1403-13. PubMed ID: 10974076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
    Osipo C; Gajdos C; Liu H; Chen B; Jordan VC
    J Natl Cancer Inst; 2003 Nov; 95(21):1597-608. PubMed ID: 14600092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
    Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
    Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.
    Sommer A; Hoffmann J; Lichtner RB; Schneider MR; Parczyk K
    J Steroid Biochem Mol Biol; 2003 May; 85(1):33-47. PubMed ID: 12798355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.
    Zhang X; Ding L; Kang L; Wang ZY
    PLoS One; 2012; 7(1):e30174. PubMed ID: 22276155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
    Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
    Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
    Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
    Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors.
    Cañas A; López-Sánchez LM; Valverde-Estepa A; Hernández V; Fuentes E; Muñoz-Castañeda JR; López-Pedrera C; De La Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
    Breast Cancer Res; 2012 Dec; 14(6):R153. PubMed ID: 23216744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
    Zhang X; Diaz MR; Yee D
    Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis.
    Mattingly KA; Ivanova MM; Riggs KA; Wickramasinghe NS; Barch MJ; Klinge CM
    Mol Endocrinol; 2008 Mar; 22(3):609-22. PubMed ID: 18048642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
    Kim C; Tang G; Pogue-Geile KL; Costantino JP; Baehner FL; Baker J; Cronin MT; Watson D; Shak S; Bohn OL; Fumagalli D; Taniyama Y; Lee A; Reilly ML; Vogel VG; McCaskill-Stevens W; Ford LG; Geyer CE; Wickerham DL; Wolmark N; Paik S
    J Clin Oncol; 2011 Nov; 29(31):4160-7. PubMed ID: 21947828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer.
    Roldán G; Delgado L; Musé IM
    Cancer Biol Ther; 2006 May; 5(5):505-10. PubMed ID: 16582598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 39. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor.
    Coser KR; Wittner BS; Rosenthal NF; Collins SC; Melas A; Smith SL; Mahoney CJ; Shioda K; Isselbacher KJ; Ramaswamy S; Shioda T
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14536-41. PubMed ID: 19706540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.